TNGX logo

Tango Therapeutics (TNGX)

Profile

Full Name

Tango Therapeutics, Inc.

Ticker Symbol

TNGX

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

September 3, 2020

Indexes

Not included

Website

http://www.tangotx.com

Employees

155

Key Details

Price

$1.29(+0.78%)

Market cap

$139.46M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$42.07M(+15.17% YoY)

Annual EPS

-$1.19(-10.19% YoY)

PE ratio

-

Next earnings date

May 8, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$1.29
TNGX price is $1.29

30-Day Relative Volume

0.63
TNGX 30-day relative volume is 0.63

Price Performance

Price Today change

+0.78%
TNGX price is up +0.78% today

Price YTD change

-58.25%
TNGX price is down -58.25% since January 1st

Price 1-year change

-82.71%
TNGX price is down -82.71% year-on-year

Price 3-year change

-83.12%
TNGX price is down -83.12% over the past 3 years

Price Range

Price All-time high

$18.84
TNGX price is currently -93.15% below its historical high of $18.84

Price 3-year low

$1.11
TNGX price is currently +16.22% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$139.46M
TNGX market capitalization is $139.46 million

Market cap 3-year change

-79.19%
TNGX market capitalization is down -79.19% over the past 3 years

Market cap All-time high

$1.51B
TNGX market capitalization is currently -90.78% below its historical high of $1.51 billion

Market cap sector rank

52.06%
TNGX market capitalization is higher than 52.06% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+1.29%
TNGX shares outstanding is up +1.29% year-on-year

Shares Outstanding 3-Year Change

+23.25%
TNGX shares outstanding is up +23.25% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.19
TNGX beta is 1.19

200-day SMA

$5.32
TNGX price is currently -75.74% below its 200-day simple moving average

50-day SMA

$1.89
TNGX price is currently -31.87% below its 50-day simple moving average

RSI

37.74
TNGX 14-day relative strength index is 37.74

Volume

0.63
TNGX 30-day relative volume is 0.63

ATR

$0.16
TNGX average true range is $0.16

10-day Historical Volatility

120.56%
TNGX 10-day historical volatility is 120.56%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$42.07M
TNGX annual revenue is $42.07 million

Revenue Analysts estimate

$29.09M
TNGX annual revenue is currently +44.60% higher than the consensus analysts' forecast

Revenue 1-year change

+15.17%
TNGX annual revenue is up +15.17% year-on-year

Revenue Sector rank

44.9%
TNGX annual revenue is higher than 44.9% of companies in Healthcare sector

EPS

EPS

-$1.19
TNGX annual earnings per share is -$1.19

EPS Analysts estimate

-$1.37
TNGX annual earnings per share is currently -13.45% lower than the consensus analysts' forecast

EPS 1-year change

-10.19%
TNGX annual earnings per share is down -10.19% year-on-year

EPS Sector rank

52.07%
TNGX annual earnings per share is higher than 52.07% of companies in Healthcare sector

Profit

Gross profit

-
TNGX annual gross profit value is unknown

Gross margin

-
TNGX annual gross profit margin value is unknown

Operating profit

-$145.59M
TNGX annual operating income is -$145.59 million

Operating margin

-346.09%
TNGX annual operating profit margin is -346.09%

Net income

-$130.30M
TNGX annual net profit is -$130.30 million

Net margin

-309.73%
TNGX annual net profit margin is -309.73%

Expenses

Total expenses

$187.66M
TNGX annual total expenses is $187.66 million

Operating expenses

$187.66M
TNGX annual total operating expenses is $187.66 million

Cost of goods sold

-
TNGX annual cost of goods sold value is unknown

Selling, general & administrative expenses

$43.75M
TNGX annual SGA is $43.75 million

Depreciation and amortization

$2.50M
TNGX annual depreciation & amortization is $2.50 million

Interest expense

-
TNGX annual interest expense value is unknown

Income tax

$208.00K
TNGX annual income tax is $208.00 thousand

EBIT & EBITDA

EBIT

-$145.59M
TNGX annual earnings before interest & taxes is -$145.59 million

EBITDA

-$143.10M
TNGX annual EBITDA is -$143.10 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$316.49M
TNGX annual total assets is $316.49 million

Non current assets

$50.15M
TNGX annual long term assets is $50.15 million

Current assets

$266.34M
TNGX annual total current assets is $266.34 million

Cash and cash equivalents

$69.53M
TNGX annual cash & cash equivalents is $69.53 million

Accounts receivable

-
TNGX annual accounts receivable value is unknown

Inventory

-
TNGX annual inventory value is unknown

Liabilities

Total liabilities

$116.97M
TNGX annual total liabilities is $116.97 million

Long term liabilities

$78.81M
TNGX annual total long term liabilities is $78.81 million

Current liabilities

$38.17M
TNGX annual total current liabilities is $38.17 million

Accounts payable

$1.60M
TNGX annual accounts payable is $1.60 million

Debt

Total debt

$36.49M
TNGX annual total debt is $36.49 million

Total debt 1-year change

-6.24%
TNGX annual total debt is down -6.24% year-on-year

Long term debt

$34.04M
TNGX annual long term debt is $34.04 million

Short term debt

$2.45M
TNGX annual short term debt is $2.45 million

Equity & Capital

Shareholders equity

$199.52M
TNGX annual stockholders equity is $199.52 million

Book value

$199.52M
TNGX annual book value is $199.52 million

Retained earnings

-$501.56M
TNGX annual retained earnings is -$501.56 million

Working capital

$228.17M
TNGX annual working capital is $228.17 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$131.50M
TNGX annual cash flow from operations is -$131.50 million

Cash from operations 1-year change

-11.46%
TNGX annual cash flow from operations is down -11.46% year-on-year

Cash from investing

$86.13M
TNGX annual cash flow from investing activities is $86.13 million

Cash from investing 1-year change

+107.9%
TNGX annual cash flow from investing activities is up +107.9% year-on-year

Cash from financing

$47.66M
TNGX annual cash flow from financing activities is $47.66 million

Cash from financing 1-year change

-42.16%
TNGX annual cash flow from financing activities is down -42.16% year-on-year

CAPEX

CAPEX

$754.00K
TNGX annual capital expenditures is $754.00 thousand

CAPEX 1-year change

-50.59%
TNGX annual capital expenditures is down -50.59% year-on-year

Free Cash Flow

Free cash flow

-$132.25M
TNGX annual free cash flow is -$132.25 million

Free cash flow 1-year change

-10.67%
TNGX annual free cash flow is down -10.67% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
TNGX annual gross profit margin value is unknown

Operating margin

-346.09%
TNGX annual operating profit margin is -346.09%

Net margin

-309.73%
TNGX annual net profit margin is -309.73%

ROA & ROE

ROA

-36.24%
TNGX annual return on assets is -36.24%

ROE

-57.58%
TNGX annual return on equity is -57.58%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
TNGX price to earnings ratio value is unknown

PE ratio Sector rank

-
TNGX price to earnings ratio is unknown

PB Ratio

PB ratio

0.70
TNGX price to book ratio is 0.70

PB ratio Sector rank

36.82%
TNGX price to book ratio is higher than 36.82% of companies in Healthcare sector

PS Ratio

PS ratio

3.31
TNGX price to sales ratio is 3.31

PS ratio Sector rank

55.9%
TNGX price to sales ratio is higher than 55.9% of companies in Healthcare sector

Enterprise value

Enterprise value

$106.42M
TNGX enterprise value is $106.42 million

Enterprise value Sector rank

51.03%
TNGX enterprise value is higher than 51.03% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-0.74
TNGX EV/EBITDA is -0.74

EV/EBITDA Sector rank

47.22%
TNGX EV/EBITDA is higher than 47.22% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

6.98
TNGX annual current ratio is 6.98

Quick ratio

-
TNGX annual quick ratio value is unknown

Leverage

Debt to equity

0.00
TNGX annual debt to equity ratio is 0.00

Interest coverage ratio

-
TNGX annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
TNGX piotroski f-score value is unknown

Altman Z-Score

-2.02
TNGX altman z-score is -2.02

Analyst ratings

Recent major analysts updates

Apr 14, 25 HC Wainwright & Co.
Buy
Dec 5, 24 Cantor Fitzgerald
Overweight
Nov 11, 24 B. Riley Securities
Buy
Nov 8, 24 HC Wainwright & Co.
Buy
Nov 7, 24 Guggenheim
Buy
Oct 28, 24 HC Wainwright & Co.
Buy
Sep 10, 24 HC Wainwright & Co.
Buy
Aug 8, 24 Wedbush
Outperform
Jul 17, 24 Jefferies
Buy
Jul 9, 24 HC Wainwright & Co.
Buy

Institutional Ownership

Similar stocks

CATX logo
Perspective Therapeutics (CATX)
SLN logo
Silence Therapeutics (SLN)
FENC logo
Fennec Pharmaceuticals (FENC)
CGEN logo
Compugen (CGEN)
PROF logo
Profound Medical (PROF)
FDMT logo
4D Molecular Therapeutics (FDMT)
SGHT logo
Sight Sciences (SGHT)
PBYI logo
Puma Biotechnology (PBYI)
CLLS logo
Cellectis SA (CLLS)
  • What is the ticker symbol for Tango Therapeutics?
  • Does Tango Therapeutics pay dividends?
  • What sector is Tango Therapeutics in?
  • What industry is Tango Therapeutics in?
  • What country is Tango Therapeutics based in?
  • When did Tango Therapeutics go public?
  • Is Tango Therapeutics in the S&P 500?
  • Is Tango Therapeutics in the NASDAQ 100?
  • Is Tango Therapeutics in the Dow Jones?
  • When was Tango Therapeutics's last earnings report?
  • When does Tango Therapeutics report earnings?
  • Should I buy Tango Therapeutics stock now?

What is the ticker symbol for Tango Therapeutics?

The ticker symbol for Tango Therapeutics is NASDAQ:TNGX

Does Tango Therapeutics pay dividends?

No, Tango Therapeutics does not pay dividends

What sector is Tango Therapeutics in?

Tango Therapeutics is in the Healthcare sector

What industry is Tango Therapeutics in?

Tango Therapeutics is in the Biotechnology industry

What country is Tango Therapeutics based in?

Tango Therapeutics is headquartered in United States

When did Tango Therapeutics go public?

Tango Therapeutics's initial public offering (IPO) was on September 3, 2020

Is Tango Therapeutics in the S&P 500?

No, Tango Therapeutics is not included in the S&P 500 index

Is Tango Therapeutics in the NASDAQ 100?

No, Tango Therapeutics is not included in the NASDAQ 100 index

Is Tango Therapeutics in the Dow Jones?

No, Tango Therapeutics is not included in the Dow Jones index

When was Tango Therapeutics's last earnings report?

Tango Therapeutics's most recent earnings report was on Feb 27, 2025

When does Tango Therapeutics report earnings?

The next expected earnings date for Tango Therapeutics is May 8, 2025

Should I buy Tango Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page